CSL (OTCMKTS:CSLLY) Shares Gap Up – Still a Buy?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $17.43, but opened at $18.77. CSL shares last traded at $18.96, with a volume of 4,785 shares traded.

Wall Street Analyst Weigh In

CSLLY has been the topic of a number of recent analyst reports. Zacks Research lowered CSL from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Canaccord Genuity Group lowered CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Jefferies Financial Group lowered CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Finally, Citigroup lowered CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.

CSL Price Performance

The business has a 50-day simple moving average of $20.66 and a 200 day simple moving average of $39.97. The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.